secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001104659-24-030773
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma FY2023 net loss $22.3M; cash $19.1M; NXP800 data update expected March 2024
--------------------------------------------------------------------------------

- Cash and cash equivalents $19.1M at Dec 31, 2023, down from $20.0M at Dec 31, 2022.
- Net loss for FY2023 was $22.3M vs $19.1M in FY2022; includes $4.7M non-cash stock compensation.
- R&D expenses increased to $15.4M from $13.2M; G&A increased to $7.5M from $6.0M.
- NXP800 Phase 1b preliminary data update expected in March 2024 for platinum-resistant ARID1a-mutated ovarian cancer.
- NXP900 Phase 1a dose escalation initiated; multiple clinical data readouts expected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465924030773/0001104659-24-030773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465924030773/tm247868d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-030773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer